FDA approves Valeant's psoriasis drug with warning, REMS

FDA approved Siliq brodalumab from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to treat adults with moderate to severe plaque psoriasis. Next half, the company expects to launch the IgG2 mAb against IL-17 receptor (IL17R; IL17RA).

Siliq's label includes a boxed warning noting risks of suicidal ideation and behavior, and the drug has a REMS. It is approved to treat patients who are candidates for systemic therapy or phototherapy and have failed to respond or have stopped responding to other systemic therapies...